Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 201–300 of 1,003
Ornoy, A., Weinstein‐Fudim, L., & Ergaz, Z. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00316 · Cited by 153
Risk factors diagnosis prognosis and treatment of autism
Al-Dewik, N. I. E. (2020) · Frontiers in bioscience · doi:10.2741/4873 · Cited by 153
Proteolysis-targeting chimeras with reduced off-targets
Nguyen, T. M., Sreekanth, V., Deb, A., Kokkonda, P., Tiwari, P. K., Donovan, K. A., Shoba, V., Chaudhary, S. K., Mercer, J. A. M., Lai, S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-023-01379-8 · Cited by 139
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Lagrue, K., Carisey, A., Morgan, D. J., Chopra, R., & Davis, D. M. (2015) · Blood · doi:10.1182/blood-2015-01-625004 · Cited by 132
Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 130
Collins, I., Wang, H., Caldwell, J. J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 137
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438101 · Cited by 130
Sandhu, A., Handa, H., & Abe, M. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/44/442001 · Cited by 143
Self-citationStructural basis of thalidomide enantiomer binding to cereblon
Mori, T., Ito, T., Liu, S., Ando, H., Sakamoto, S., Yamaguchi, Y., Tokunaga, E., Shibata, N., Handa, H., & Hakoshima, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-19202-7 · Cited by 128
Self-citationRegulatory functions of the Mediator kinases CDK8 and CDK19
Fant, C. B., & Taatjes, D. J. (2018) · Transcription · doi:10.1080/21541264.2018.1556915 · Cited by 141
Environmental Impact on Vascular Development Predicted by High-Throughput Screening
Kleinstreuer, N. C., Judson, R. S., Reif, D. M., Sipes, N. S., Singh, A. V., Chandler, K. J., DeWoskin, R., Dix, D. J., Kavlock, R. J., & Knudsen, T. B. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1103412 · Cited by 133
Zebrafish as a model for vertebrate hematopoiesis
Ellett, F. E., & Lieschke, G. J. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.05.004 · Cited by 138
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Wang, K., Zhang, T., Lei, Y., Li, X., Jiang, J., Lan, J., Liu, Y., Chen, H., Gao, W., Xie, N., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1409405 · Cited by 134
Discovery of E3 Ligase Ligands for Target Protein Degradation
Lee, J., Lee, Y., Jung, Y. M., Park, J. H., Yoo, H. S., & Park, J. (2022) · Molecules · doi:10.3390/molecules27196515 · Cited by 137
How Thalidomide Works Against Cancer
Stewart, A. K. (2014) · Science · doi:10.1126/science.1249543 · Cited by 124
Mycobacterium Leprae –Host-Cell Interactions and Genetic Determinants in Leprosy: an Overview
Pinheiro, R. O., Sales, J. D. S., Sarno, E. N., & Sampaio, E. P. (2011) · Future Microbiology · doi:10.2217/fmb.10.173 · Cited by 136
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 119
Protein kinases: drug targets for immunological disorders
Castelo‐Soccio, L. A., Kim, H., Gadina, M., Schwartzberg, P. L., Laurence, A. D. J., & O’Shea, J. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00877-7 · Cited by 136
Adolph, K. E., & Robinson, S. R. (2015) · Handbook of Child Psychology and Developmental Science · doi:10.1002/9781118963418.childpsy204 · Cited by 135
Sehgal, K., Das, R., Zhang, L., Verma, R., Deng, Y., Kocoglu, M., Vasquez, J., Koduru, S., Ren, Y., Wang, M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611426 · Cited by 132
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0366-7 · Cited by 134
Self-citationMolecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 134
Self-citationA bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 134
Emerging therapies targeting the ubiquitin proteasome system in cancer
Weathington, N. M., & Mallampalli, R. K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71602 · Cited by 124
Chen, H., Liu, J., Kaniskan, H. Ü., Wei, W., & Jin, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00901 · Cited by 118
The Zebrafish: A Powerful Platform for In Vivo , HTS Drug Discovery
Delvecchio, C., Tiefenbach, J., & Krause, H. M. (2011) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0346 · Cited by 133
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, B. P., Ward, C. C., & Nomura, D. K. (2023) · Biochemistry · doi:10.1021/acs.biochem.1c00464 · Cited by 132
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Bjorklund, C. C., Baladandayuthapani, V, Lin, H. Y., Jones, R. J., Kuiatse, I., Wang, H., Yang, J., Shah, J. J., Thomas, S. K., Wang, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.174 · Cited by 131
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
Yang, C.-Y., Qin, C., Bai, L., & Wang, S. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.04.001 · Cited by 121
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
Zhao, M.-M., Lu, J., Li, S., Wang, H., Cao, X., Li, Q., Shi, T.-T., Matsunaga, K., Chen, C., Huang, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25952-2 · Cited by 123
Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare
Smith, C. I. E., Bergman, P., & Hagey, D. W. (2022) · iScience · doi:10.1016/j.isci.2022.104698 · Cited by 130
Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12338 · Cited by 128
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 110
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Targeted protein degradation and the enzymology of degraders
Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126
Protein Degradation and the Pathologic Basis of Disease
Hanna, J., Guerra-Moreno, A., Ang, J., & Micoogullari, Y. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.09.004 · Cited by 111
Small molecule photocatalysis enables drug target identification via energy transfer
Trowbridge, A., Seath, C. P., Rodriguez‐Rivera, F. P., Li, B. X., Dul, B. E., Schwaid, A. G., Buksh, B. F., Geri, J. B., Oakley, J. V., Fadeyi, O., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208077119 · Cited by 126
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44237-4 · Cited by 97
Pattern formation during electrochemical and liquid metal dealloying
McCue, I., Karma, A., & Erlebacher, J. (2018) · MRS Bulletin · doi:10.1557/mrs.2017.301 · Cited by 123
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Lu, P., Cheng, Y., Xue, L., Ren, X., Xu, X., Chen, C., Cao, L., Li, J., Wu, Q., Sun, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.015 · Cited by 125
Hu, M., Zhou, W., Wang, Y., Yao, D., Ye, T., Yao, Y., Chen, B., Liu, G., Yang, X., Wang, W., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.010 · Cited by 122
Histone H2B ubiquitin ligase RNF20 is required for MLL -rearranged leukemia
Wang, E., Kawaoka, S., Yu, M., Shi, J., Ni, T., Yang, W., Zhu, J., Roeder, R. G., & Vakoc, C. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301045110 · Cited by 121
“Targeting of other E3 ligase proteins with known drugs provides proof-ofprinciple that potent small-molecule inhibitors can be developed against this class of enzymes (46, 47).”
BackgroundTaylor, K. L., Grant, N. J., Temperley, N. D., & Patton, E. E. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-11 · Cited by 121
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
Łukasik, P., Baranowska‐Bosiacka, I., Kulczycka, K., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062806 · Cited by 120
Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B
Hannah, J., & Zhou, P. (2015) · Gene · doi:10.1016/j.gene.2015.08.064 · Cited by 110
Mayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 109
Bhatt, P. K., Kloock, C., & Comenzo, R. L. (2023) · Current Oncology · doi:10.3390/curroncol30020179 · Cited by 120
Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., & Naito, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.019 · Cited by 118
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 118
Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition
Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L. A., DeMarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2025) · Science · doi:10.1126/science.adt6736 · Cited by 117
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 116
Gopalakrishnan, R., Matta, H., Tolani, B., Triche Jr, T., & Chaudhary, P. M. (2016) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 112
Wei, S., Chen, X., McGraw, K., Zhang, L., Komrokji, R., Clark, J., Caceres, G., Billingsley, D., Sokol, L., Lancet, J., et al. (2013) · Oncogene · doi:10.1038/onc.2012.139 · Cited by 101
Targeted protein knockdown using small molecule degraders
Raina, K., & Crews, C. M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.016 · Cited by 110
Targeted protein degrader development for cancer: advances, challenges, and opportunities
Fang, Y., Wang, S., Han, S., Zhao, Y., Yu, C., Liu, H., & Li, N. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.003 · Cited by 115
The clinical significance of cereblon expression in multiple myeloma
Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.08.015 · Cited by 113
Proteome-scale discovery of protein degradation and stabilization effectors
Poirson, J., Cho, H., Dhillon, A., Haider, S., Imrit, A. Z., Lam, M. H. Y., Alerasool, N., Lacoste, J., Mizan, L., Wong, C. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07224-3 · Cited by 115
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Perkins, E. J., Ankley, G. T., Crofton, K. M., García‐Reyero, N., LaLone, C. A., Johnson, M. S., Tietge, J. E., & Villeneuve, D. L. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1306638 · Cited by 112
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
To, K. K. W., Xing, E., Larue, R. C., & Li, P. (2023) · Molecules · doi:10.3390/molecules28073043 · Cited by 112
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy
Shortt, J., Hsu, A. K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2012.599 · Cited by 112
Zhu, Y. X., Shi, C.-X., Bruins, L. A., Wang, X., Riggs, D. L., Porter, B., Ahmann, J. M., de Campos, C. B., Braggio, E., Bergsagel, P. L., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0173-0 · Cited by 100
Current advances in photocatalytic proximity labeling
Knutson, S. D., Buksh, B. F., Huth, S. W., Morgan, D. C., & MacMillan, D. W. C. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.012 · Cited by 111
Current knowledge of environmental exposure in children during the sensitive developmental periods
Perlroth, N. H., & Branco, C. W. C. (2016) · Jornal de Pediatria · doi:10.1016/j.jped.2016.07.002 · Cited by 111
Trial Watch: DNA vaccines for cancer therapy
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 110
The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies
Zhu, Y., Wang, Z., Li, Y., Peng, H., Liu, J., Zhang, J., & Xiao, X. (2023) · Cancers · doi:10.3390/cancers15041219 · Cited by 110
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 110
Edelmann, M. J., Nicholson, B., & Kessler, B. M. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002031 · Cited by 109
Steensma, D. P. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.001 · Cited by 108
Genetic and non-genetic animal models for autism spectrum disorders (ASD)
Ergaz, Z., Weinstein-Fudim, L., & Ornoy, A. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.04.024 · Cited by 107
Know your target, know your molecule
Bunnage, M. E., Gilbert, A. M., Jones, L. H., & Hett, E. C. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1813 · Cited by 107
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Kostic, M., & Jones, L. H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.006 · Cited by 91
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 94
Lenalidomide induces degradation of IKZF1 and IKZF3
Krönke, J., Hurst, S. N., & Ebert, B. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.941742 · Cited by 95
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
Gandhi, A. K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12622 · Cited by 106
“The protein cereblon (CRBN) was first described to be the molecular target of thalidomide in a seminal paper by Ito et al (2010), linking its role to teratogenic effects by thalidomide in zebrafish and chicks.”
BackgroundInfluentialPROTAC technology: From drug development to probe technology for target deconvolution
Yan, S., Zhang, G., Luo, W., Xu, M., Peng, R., Du, Z., Liu, Y., Bai, Z., Xiao, X., & Qin, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116725 · Cited by 106
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia
Riches, J. C., & Gribben, J. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.01.003 · Cited by 105
PROTAC-mediated crosstalk between E3 ligases
Steinebach, C., Kehm, H., Lindner, S., Vu, L. P., Köpff, S., López Mármol, Á., Weiler, C., Wagner, K. G., Reichenzeller, M., Krönke, J., et al. (2019) · Chemical Communications · doi:10.1039/c8cc09541h · Cited by 97
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 104
Lacy, M. Q., & McCurdy, A. B. R. (2013) · Blood · doi:10.1182/blood-2013-05-484782 · Cited by 104
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex
Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0405-9 · Cited by 103
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Disruption of embryonic vascular development in predictive toxicology
Knudsen, T. B., & Kleinstreuer, N. (2011) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20223 · Cited by 103
Huang, X., Di Liberto, M., Jayabalan, D., Liang, J., Ely, S., Bretz, J., Shaffer, A. L., Louie, T., Chen, I., Randolph, S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415984 · Cited by 102
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Zhou, S. Y., Wang, F., Hsieh, T.-C., WU, J. M., & Wu, E. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990198 · Cited by 101
Functional modulation of AMP-activated protein kinase by cereblon
Lee, K. M., Jo, S., Kim, H., Lee, J., & Park, C.-S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.005 · Cited by 93
Lucas, X., & Ciulli, A. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.015 · Cited by 101
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Rasco, D. W., Papadopoulos, K. P., Pourdehnad, M., Gandhi, A. K., Hagner, P. R., Li, Y., Wei, X., Chopra, R., Hege, K., DiMartino, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1203 · Cited by 95
Wang, T., Liu, X.-H., Guan, J., Ge, S., Wu, M.-B., Lin, J.-P., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 93
Trial watch: DNA vaccines for cancer therapy
Senovilla, L., Vacchelli, E., Garcia, P., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23803 · Cited by 99
CRL4ACRBN E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis
Liu, J., Ye, J., Zou, X., Xu, Z., Feng, Y., Zou, X., Chen, Z., Li, Y., & Cang, Y. (2014) · Nature Communications · doi:10.1038/ncomms4924 · Cited by 99
Novel strategies to target the ubiquitin proteasome system in multiple myeloma
Lub, S., Maes, K., Menu, E., Bruyne, E. D., Vanderkerken, K., & Valckenborgh, E. V. (2015) · Oncotarget · doi:10.18632/oncotarget.6658 · Cited by 98
The teratogenic effects of thalidomide on limbs
Vargesson, N. (2018) · Journal of Hand Surgery (European Volume) · doi:10.1177/1753193418805249 · Cited by 98
Targeting the β-catenin signaling for cancer therapy
Zhang, X., Wang, L., & Qu, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104794 · Cited by 98
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.